Capital Performance Advisors LLP bought a new position in Incyte Co. (NASDAQ:INCY – Free Report) in the third quarter, ...

Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year and ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...

Shares of Incyte (NASDAQ:INCY) jumped 8% after the company reported better-than-expected Q3 revenue and raised sales guidance ...

Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.

Incyte (NASDAQ:INCY) is scheduled to announce Q3 earnings results on Tuesday, October 29th, before market open. The consensus ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

On Friday, Incyte Corp (INCY) stock saw a modest uptick, ending the day at $83.38 which represents a slight increase of $1.04 or 1.26% from the prior close of $82.34. The stock opened at $82.59 and ...